UPDATE ON THE ROAD TO THE CURE - OCTOBER 2021

ICBII UPDATE ON THE ROAD TO THE CURE

Ram S. Bhatt, PhD., Chief Science Officer

LA JOLLA, CA / Sept. 22, 2021/PRNewswire/ Innovative California Biosciences International, Inc., (“ICBII”), has announced the approval of its seventh patent for Blood-Brain Barrier (BBB) Permeable Peptide Compositions. Approval of this patent further strengthens the Company’s IP portfolio of its SMART* Molecules technology and brings the management closer to the clinical trials. ICBII’s SMART molecules technology is blazing the path to non-invasive diagnosis and potentially curing brain diseases by delivering drugs to targeted sites that have not been possible so far.  

                SMART* is an acronym for Specific Molecular Architecture for Recognition and Therapy. An estimated 98% of all small-molecule drugs and nearly 100% of macromolecular drugs, capable of potentially curing brain diseases, cannot cross the BBB into the central nervous system. The drugs that do cross the blood-brain barrier only provide short-term symptomatic relief without altering disease progression.   

                “With efficient brain uptake, SMART molecules have cleared up to 66% of aggregated amyloid-beta and alpha-synuclein with once weekly, low dose injections over eight to twelve weeks in animal models of Alzheimer’s and Parkinson’s diseases, respectively. This provides ICBII scientists with the necessary tools to potentially cure otherwise incurable brain disorders and improve the debilitation of patients afflicted by diseases such as Alzheimer’s, Parkinson’s, Multiple System Atrophy (MSA), and Glioblastoma,” says Ram Bhatt, Founder and Chief Scientist of ICBII. 

                Comprised of heavy-chain only antibodies, SMART Molecules is a platform technology with applications that extends beyond brain diseases to cancer, infectious, autoimmune, rare, age- and diabetes-related macular degeneration.  

About ICBII: The Company was founded for the sole purpose of addressing unmet therapeutic needs for the central nervous system and difficult to cure cancer diseases. The blood-brain barrier has effectively excluded the brain from the entire biotech revolution. With its SMART molecules technology, ICBII’s mission is to impact the lives of millions of patients worldwide by relieving their suffering with affordable drugs. 

Forward-Looking Statements: This press release may contain forward-looking statements, including ICBII’s development of SMART Molecules for altering the course of central nervous system diseases. These statements are based on our current results obtained in vivo studies and may prove not to be accurate. Actual results may differ materially from those anticipated due to known and unknown risks, uncertainties, and other factors. 

WOULD YOU LIKE TO HELP get ICBII’s drugs to market faster? The joy of being a part of this historical event can be had by helping ICBI find the funds to bring these trials to fruition through your investing, and by finding others with the financial ability and humanitarian mindset to accomplish the, until now, impossible. Please contact ICBI directly through their website ICBII.com or by phone 858-455-9880, or contact Jo Rosen at PRO for a personal introduction to the scientists.

IMAGINE the world without Parkinson’s, MSA, or Alzheimer’s disease.              

JUST IMAGINE.